In the present study, a liver-specific conditional GPRC6A knockout mouse model was used to explore the potential mechanisms underlying the ability of uncarboxylated osteocalcin to alleviate NAFLD. Here, GPRC6A is linked to metabolic dysfunction-associated steatotic liver disease.